Asthma & COPD 2017
March 29 - 30, 2017 - London UKSMi Group
zgale@smi-online.co.uk
Phone:02078276132
Aimed at senior scientists and respiratory and inhalation specialists, Asthma & COPD 2017 will reflect on the ongoing issues and latest developments of these two diseases. With a carefully selected panel of industry experts, the 2017 event will address the latest challenges and changes in the fields of asthma and COPD. The agenda will explore novel approaches to treatment, including cutting edge developments in triple combination therapies and phenotyping. As well as identify challenges to device development and delivery, deepen our understanding of the problems relating to these diseases, and discuss the hot topic of electronic health monitoring. Featured Speakers: Quan Yang, Pharmaceutical Assessor, MHRA Stephen Beckman, Head of Global Respiratory and Allergy, Mylan Outi Vaarala, Vice President, Head of Translational Biology, AstraZeneca Ewan Walters, Medical Director, Teva UK David Leather, Global Medical Affairs Leader, GlaxoSmithKline Stefan Leiner, Chemical-Pharmaceutical Expert, Boehringer Ingelheim Neelima Khairatkar Joshi, Senior Vice President & Head of Drug Discovery, Glenmark Pharmaceuticals Christopher Stevenson, Venture Leader COPD Interception, Janssen Marianna Alacqua, Senior Global Medical Affairs Leader of Respiratory Biologics, AstraZeneca Frank Thielmann, Operational Lead Inhalation New Solids, Novartis and many more... Exclusive highlights in 2016: Updates from the MHRA on the regulatory challenge to developing inhalation devices Overcome hurdles to the success of new devices with Boehringer Ingelheim Janssen’s innovative approaches to COPD interception Track the emerging trends in targeted treatment with biomarkers and biologics with MedImmune Real time data collection’ – an exclusive case study presentation on GSK’s pioneering ‘Salford Lung study’ WORKSHOPS: Both interactive workshops have been carefully selected to complement the topics covered in the conference agenda.